Pharma AI
Make smarter clinical development decisions with Onc.AI
Ingest
- Easily upload routine CT scans—no manual annotations required.
- Seamlessly handles both baseline and follow-up scans.
- Automatic quality control ensures data integrity.
- Secure, fully de-identified data pipeline.
Analyze
Advanced deep learning models extract comprehensive imaging biomarkers:
- Tumor burden, Vascularity, Body composition, Organ morphology
- Additional clinically relevant features
- Generates structured, standardized scores at both individual patient and cohort levels.
- Provides intuitive visual and tabular outputs for immediate review or further analysis.
Predict & Apply
- Delivers actionable insights for survival prediction, early therapeutic response, and patient stratification.
- Enables early identification of high-risk patients.
- Facilitates effective comparison of treatment arms or dosing cohorts.
- Enhances confidence in critical go/no-go trial decisions.
Science
Our Partners
Benefits
Fully Automated, End-to-End Deep Learning Pipeline
Effortless Integration: Seamlessly fits into existing clinical workflows.
No Annotations Required: Eliminates manual annotation, saving significant time and cost.
Completely Automated: Provides consistent, objective biomarker assessments.
Smarter Clinical Trial Design
- Enhance trial precision and efficiency with AI-driven patient stratification.
- Utilize advanced deep learning biomarkers to balance treatment arms.
- Apply sophisticated risk scores and propensity score matching to optimize patient selection.
Accelerate Early-Phase Decisions
- Quickly gain data-driven insights into therapeutic efficacy.
- Inform critical go/no-go decisions early in the clinical process.
- Efficiently compare treatment responses across various dose levels.
Improve Phase 3 Success Rates
- Refine patient selection and tailor endpoint strategies.
- Leverage robust deep learning radiomic biomarkers for quantitative outcome predictions.
- Enhance confidence in pivotal clinical trial decisions.
Clinical AI
Inform treatment decision-making for metastatic lung cancer patients treated with immunotherapy.
This product is currently investigational, not yet cleared by the FDA, and not approved for clinical use.
How it Works
Leverage patient-specific prognostic risk assessments powered by advanced deep-learning AI biomarkers trained on extensive real-world datasets to refine clinical decisions and enhance patient management.
Order the Test
Physician initiates the test order; Onc.AI securely retrieves and processes routine clinical CT scans, no additional input or manual annotation required.
AI-Driven Analysis
Sophisticated deep-learning AI models automatically extract clinically relevant imaging biomarkers:
- Tumor radiomic signature (intensity, texture, morphology)
- Multi-site tumor burden (volume and spatial distribution across affected organs)
- Vascular structure and morphology
- Advanced body composition metrics
Actionable Reporting
Within 24 hours, clinicians receive a comprehensive and intuitive report featuring:
- High/low-risk stratification for 12-month overall survival
- Patient-specific prognostic risk scores
Facilitates informed clinical decision-making, enabling personalized treatment strategies tailored to individual patient risk.
Highlights
Clinical Solutions – Transforming Imaging into Powerful Insights
Onc.AI reveals critical insights beyond what the human eye can detect, turning routine imaging into powerful insights to inform clinical decisions.
LCM (Lung Clinical Management)
August 20th, 2024
Currently under FDA review. Rigorously externally validated using a large real-world dataset from Flatiron Health
Serial CTRS
January 24th, 2025
Granted FDA Breakthrough Device Designation. Actively engaged in accelerated review and sprint process with FDA.
Science
Our Clinical Partners
Contact Us
Have questions? Fill out the form and
our team will reply as soon as possible.
-
SF Bay Area
United States -
Waterloo, ON
Canada - contact@onc.ai